Providers

A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

Preventing addiction is key to ending the opioid epidemic—2020 alone saw more than 93,000 overdose deaths—as are expanding access to treatment, promoting recovery, and building a multifaceted strategy that incorporates nonopioid alternative and their coverage by providers. Although appropriate in certain situations, opioids are not a one-size-fits-all approach.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.

Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.

Patients with asthma were found to have a more than 3-fold greater risk of developing narcolepsy than those without asthma, with use of inhaled corticosteroids indicated to decrease risk.

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.

Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.

Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).

The field of ophthalmology had already been moving toward telehealth and artificial intelligence (AI) before the COVID-19 pandemic, but these changes are being accelerated now, making it crucial for ophthalmologists to learn to adapt.

Genetic profiling in recurrent and advanced breast cancer can yield actionable, smoking-gun biomarkers, Stanford Cancer Institute pathologists explained at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors.

Emergency department utilization for nonemergent ophthalmic conditions is on the rise in the United States, but presentation types vary significantly based on patient demographics, according to 2 posters presented at the American Academy of Ophthalmology (AAO) 2021 meeting.

Surgical decisions with children who have ophthalmic conditions need buy in from parents, but also the children as they get older, said William Katowitz, MD, attending surgeon in the Division of Ophthalmology at Children's Hospital of Philadelphia.

Certain ophthalmic subspecialties were more well suited for telemedicine use based on what tends to get covered in patient visits, said Darren Chen, MD student at Weill Cornell Graduate School of Medical Sciences.

The real-world visual acuity gains in age-related macular degeneration (AMD) after treatment have been inferior to those seen in clinical trials, explained a speaker during the American Academy of Ophthalmology 2021 meeting.

Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.

A recent survey of oncologists in Australia showed that while most are integrating comprehensive genomic profiling (CGP) into their practice, they lack a high level of confidence to communicate findings and to adjust patient treatment accordingly.

A discussion at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors addressed the advantages and considerations for broad and targeted genomic profiling in oncology.

Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.

Unlike other options in the past, teprotumumab actually addresses bulging eye and double vision associated with thyroid eye disease (TED), which patients primarily care about, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Whether or not a child’s vision is impacted by ptosis, there are usually alternatives to surgery, which is elective, said William Katowitz, MD, attending surgeon in the Division of Ophthalmology at Children's Hospital of Philadelphia.